Delayed Liver Test Elevations During Long‐Term Elexacaftor/Tezacaftor/Ivacaftor Therapy in Adults With Cystic Fibrosis
Pediatric Pulmonology · 2026-11 · 61 (11)
DOI: 10.1002/ppul.71920 ↗At a glance
Journal article in Pediatric Pulmonology, published online on 2026-11-16. Written by Amin Khudari and 6 co-authors. Institution: Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, California, USA. Major MEDLINE topics: Cystic Fibrosis, Chemical and Drug Induced Liver Injury, Alanine Transaminase, Indoles. 15 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Background
Drug‐induced liver injury (DILI) is a labeled risk of elexacaftor/tezacaftor/ivacaftor (ETI) that most often arises within the first year of therapy; elevations beyond that window are incompletely characterized. We hypothesized that new liver test elevations occur after the first year and are associated with identifiable host‐ and exposure‐related risk factors.
Methods
Single‐center retrospective cohort study of 124 adults with cystic fibrosis (CF) who received ETI for at least 12 months. Delayed liver test (dLT) elevations were defined as elevations occurring more than 12 months after initiation.
Results
Thirty‐six patients (29%) developed new alanine aminotransferase (ALT) elevations beyond 12 months, of whom 6 (16.7%) had no identifiable alternative contributor and were attributed to ETI. Delayed elevations were associated with male sex ( p = 0.04), F508del homozygosity ( p = 0.05), prior CF liver disease ( p < 0.001), acetaminophen exposure ( p = 0.007), and concurrent infection or inflammation ( p = 0.002). Six patients had clinically significant elevations exceeding 3 times the upper limit of normal (ULN); in these, total bilirubin remained normal and hepatic imaging and elastography identified no alternative etiology, and Roussel Uclaf Causality Assessment Method scoring classified five as “possible” and one as “probable” DILI. ETI dose reduction normalized or stabilized ALT in most, with only modest spirometric change.
Conclusions
New liver test elevations occurred after the first year of ETI in a substantial minority of adults with CF, and in 16.7% no alternative cause was identified. These findings support continued, risk‐informed liver test monitoring beyond the first year.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, California, USA.
- Division of Gastrointestinal and Liver Diseases, Keck Medicine of USC, University of Southern California, Los Angeles, California, USA.
- Division of Pulmonary and Critical Care Medicine, Keck Medicine of USC, University of Southern California, Los Angeles, California, USA.
ORCID profiles: Amin Khudari, Paul M Beringer
Cite
APA
Khudari, A., Sislyan, S., Haddad, S., Dukewich, M., Rao, A. P., Chung, P., & Beringer, P. M. (2026). Delayed Liver Test Elevations During Long‐Term Elexacaftor/Tezacaftor/Ivacaftor Therapy in Adults With Cystic Fibrosis. Pediatric Pulmonology, 61(11). https://doi.org/10.1002/ppul.71920
Vancouver
Khudari A, Sislyan S, Haddad S, Dukewich M, Rao AP, Chung P, et al. Delayed Liver Test Elevations During Long‐Term Elexacaftor/Tezacaftor/Ivacaftor Therapy in Adults With Cystic Fibrosis. Pediatric Pulmonology. 2026;61(11). doi:10.1002/ppul.71920
BibTeX
@article{Khudari2026,
author = {Khudari, Amin and Sislyan, Sarkis and Haddad, Soumar and Dukewich, Matthew and Rao, Adupa P and Chung, Peter and Beringer, Paul M},
title = {Delayed Liver Test Elevations During Long‐Term Elexacaftor/Tezacaftor/Ivacaftor Therapy in Adults With Cystic Fibrosis},
journal = {Pediatric Pulmonology},
year = {2026},
volume = {61},
number = {11},
doi = {10.1002/ppul.71920}
}
EUVIMED